Germany's BioNTech and China's Shanghai Fosun Pharmaceutical on Wednesday declared the start of another COVID-19 vaccine trial in China with a total of 144 participants.

"The study is designed to support the regulatory approval process for the Chinese market and plans to confirm the safety and immunogenicity profile observed in participants in the German and US trials is similar to that of Chinese participants," BioNTech stated in a statement.